Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult challenges in modern oncology. It is a condition characterised by aggressive tumour growth and a high mortality rate, with a five-year survival rate that persists below 13% (1). Because the disease is often asymptomatic in its early stages, the majority of patients are diagnosed only after the cancer has become metastatic and unresectable. While this mutation drives the disease, the RAS protein was long